Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 20/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodophenpropit SCHEMBL22651297 | 1.00 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| Iodophenpropit SCHEMBL30632137 | 0.99 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL26687384 | 0.81 | HRH4 (0.69) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| Clobenpropit SCHEMBL49050 | 0.78 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL9534159 | 0.78 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4HRH3 | |
| SCHEMBL8805366 | 0.77 | HRH4 (0.63) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL9533886 | 0.71 | HRH4 (0.58) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL7859117 | 0.67 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL8621926 | 0.65 | HRH3 (0.60) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| Clobenpropit SCHEMBL19733457 | 0.63 | HRH4 (0.65) | HRH4TP53CYP1A2CYP3A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1687 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250085273-A1 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2025-03-13 | — | — | US | claimed |
| CN-101662966-A | packages for ophthalmic lenses containing pharmaceutical agents | JOHNSON & JOHNSON VISION CARE | 2010-03-03 | — | — | CN | claimed |
| EP-2046872-A2 | PACKAGES FOR OPHTHALMIC LENSES CONTAINING PHARMACEUTICAL AGENTS | Johson & Johnson Vision Care Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080023345-A1 | PACKAGES FOR OPHTHALMIC LENSES CONTAINING PHARMACEUTICAL AGENTS | JOHNSON & JOHNSON VISION CARE, INC. | 2008-01-31 | — | — | US | claimed |
| WO-2008008636-A2 | PACKAGES FOR OPHTHALMIC LENSES CONTAINING PHARMACEUTICAL AGENTS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| CN-1343924-A | Chinese-character 'first pyhonetic letter table-shape code' encode method and its keyboard | QIN RONGFU (CN) | 2002-04-10 | — | — | CN | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001085786-A2 | HUMAN HISTAMINE H4 RECEPTOR | WYETH (US) | 2001-11-15 | — | — | WO | disclosed |
| CN-1283108-A | Chlamydia protein, gene sequence and use thereof | ANTEX BIOLOFICS INC (US) | 2001-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1A, HTR5A, HTR3B | HRH4 445/4885TP53 3804/4885CYP1A2 1238/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | HRH4 4405/4885TP53 884/4885CYP1A2 733/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | HRH4 4319/4885TP53 2128/4885CYP1A2 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.